Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-negative status confers therapeutic sensitivity to Bevacizumab, Paclitaxel in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
In combination with paclitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.